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 Cell-Based Regenerative Therapy 
for Liver Disease 
 Kenichi  Horisawa and  Atsushi  Suzuki 
 Abstract  The liver can regenerate itself in response to acute liver damage. However, 
chronically induced liver dysfunction interferes with the liver regeneration process 
and increases the risk of onset of more severe hepatic failure, including hepatic 
cirrhosis and liver cancer. To develop more efﬁ cient therapeutics for chronic liver 
diseases, cell-based regenerative therapies using functional hepatocyte-like cells 
derived from pluripotent stem cells are actively under investigation. In addition to 
such stem cell–based approaches, recent studies have revealed that direct cell-fate 
conversion from ﬁ broblasts into hepatocyte-like cells can be induced by forced 
expression of particular sets of transcription factors in ﬁ broblasts. This phenomenon 
is known as “direct reprogramming” and is expected to be a complementary or 
alternative technology to the stem cell-based regenerative therapies. In this chapter, 
we brieﬂ y summarize the recent progress and future perspectives of studies on 
reprogramming technologies, which are directed at the development of cell-based 
regenerative therapies for liver diseases. 
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 The Liver and Disease 
 The liver is the central organ for metabolism, by which it produces energy for life 
activities and detoxiﬁ es various extrinsic and intrinsic harmful substances. In addi-
tion, the liver creates endocrine and exocrine materials, such as serum albumin, 
growth factors, and bile acids. The liver is developed from the foregut endoderm [ 1 ] 
and consists of parenchymal cells, such as hepatocytes, and various non- parenchymal 
cells, such as biliary epithelial cells, Kupffer cells, pit cells, hepatic stellate cells, 
mesothelial cells, and sinusoid endothelial cells [ 2 ]. Among the diverse kinds of cell 
populations, the major cell population in the liver is composed of hepatocytes, 
which play primary physiological roles in this organ. 
 The liver is one of the few organs capable of regeneration in the body. Since the 
ancient Greek era, the liver has been known to have a strong intrinsic regenerative 
ability in vivo. The famous “Prometheus” myth represents the rapid regeneration of 
this organ [ 3 ]. Indeed, deletion of two thirds of the total mass of the liver can be 
recovered completely in vivo [ 2 ]. However, chronic hepatitis generates a highly 
serious situation for the liver, and often leads to more severe hepatic failure, 
including hepatic cirrhosis and liver cancer. Thus, various conditions are attributed 
etiologically to chronic hepatitis. The most common cause of chronic hepatitis is 
infection by hepatotropic viruses, followed by alcoholic hepatitis, non-alcoholic 
fatty liver disease, drug-induced hepatitis, and autoimmune hepatitis [ 4 ]. 
 Expectations for Cell-Based Regenerative Therapies 
 Many types of medical treatments have been applied to patients with chronic hepa-
titis. Although anti-inﬂ ammatory drugs, such as ursodeoxycholic acid, glycyrrhizin, 
and liver extracts, are widely used to treat all types of chronic hepatitis, such 
treatments are only symptomatic therapies. For patients with viral hepatitis, 
antiviral drugs, such as interferon, corticosteroid, ribavirin, lamivudine, and 
azathioprine, have been speciﬁ cally employed. However, several side effects associ-
ated with these drugs, including fever and drug-resistant strains, appear with high 
frequency [ 4 ]. 
 In the treatment of severe liver failure, organ transplantation is the ultimate solu-
tion and has a relatively high postoperative survival rate. However, there are many 
problems to be solved, including a chronic donor shortage, ethics, and immune 
rejection [ 4 ]. Therefore, cell-based regenerative therapies, which employ in vitro- 
expanded or newly generated hepatocytes, are expected to be the next-generation 
therapies. 
 Although hepatocytes have a high proliferative ability in vivo, this potential dis-
appears immediately upon in vitro culture. Consequently, innovative technologies 
that can expand, maintain, mature, and create hepatocytes in vitro are required for 
future cell-based therapies for liver disorders. 
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 Pluripotent Stem Cell–Based Approaches to Treat Liver 
Failure 
 Among the current technologies aimed toward regenerative therapies for liver 
diseases, pluripotent stem cell–based approaches could be considered to show the 
most promise. Pluripotent stem cells can differentiate into any of the cell types 
responsible for the formation of particular tissues and organs, with the exception of 
extraembryonic tissues. Embryonic stem (ES) cells have been established as plu-
ripotent stem cells and employed in basic research toward regenerative therapies for 
liver diseases. Hepatocyte differentiation from murine ES cells is generally induced 
via methods involving embryoid body (EB) formation [ 5 – 8 ]. Although EB-derived 
hepatocyte-like cells survive and function in vivo, their low differentiation frequency 
and associated teratoma formation remain as serious problems [ 9 ]. Several studies 
have tried to purify deﬁ nitely differentiated hepatocytes or hepatic progenitor cells, 
using reporter expressions that are regulated by the promoters or enhancers of 
hepatocyte-speciﬁ c genes, including  albumin and  α-fetoprotein ( Afp ) [ 10 ,  11 ]. 
Meanwhile, other studies have revealed the molecular mechanisms that regulate 
hepatocyte differentiation. In particular, employment of a liquidity factor, activin A, 
was found to efﬁ ciently improve both the ratio of hepatocyte differentiation and the 
quality of parental ES cells [ 12 – 14 ]. Other regulatory molecules required for 
hepatocyte differentiation have also been discovered [ 15 – 17 ]. By improving the 
in vitro hepatocyte differentiation of ES cells, many researchers have succeeded in 
transplantation of mouse/human ES cell–derived hepatocyte-like cells [ 18 – 20 ]. 
 In 2006, Takahashi and Yamanaka [ 21 ] reported epoch-making artiﬁ cial stem 
cells, termed “induced pluripotent stem” (iPS) cells. These novel stem cells can be 
expected to overcome the ethical and immunological problems associated with the 
use of ES cells [ 21 ,  22 ]. Soon after the publication of their study on iPS cells, many 
research groups started to employ these novel stem cells for in vitro hepatocyte 
differentiation using methods and knowledge accumulated in studies on ES cells 
[ 23 – 26 ]. Most recently, Takebe et al. [ 27 ] reported that vascularized and functional 
human liver bud-like structures could be formed by human iPS cells in culture and 
regenerate a part of the liver tissue upon transplantation. This technology has 
brought iPS cells closer to clinical reality. Nonetheless, iPS cells still have some 
problems to be solved, including tumorigenesis after transplantation and substantial 
costs. Thus, more vigorous basic studies are required for clinical-level applications 
using iPS cell technology. 
 Direct Reprogramming 
 Development of Direct Reprogramming Technologies 
 Recently, the strategy of direct cell-fate conversion from one cell type into another 
cell type, termed “direct reprogramming”, has rapidly expanded worldwide and is 
expected to be a complementary or alternative technology for future cell-based 
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regenerative therapies using pluripotent stem cells. This method can generate both 
mature and progenitor-like cells in speciﬁ c lineages from other types of cells. Thus, 
the cells required for treatment of particular diseases could be provided from an 
alternative source of cells and used as donor cells for transplantation therapy. 
 The ﬁ rst evidence for direct reprogramming was reported in the 1980s. Davis 
et al. [ 28 ] discovered a single transcription factor, Myod, that could induce fate 
conversion of ﬁ broblasts into myoblasts. That sensational report encouraged 
researchers to look for single master transcription factors that could specify and 
govern the fate of cells in each lineage. However, studies on direct reprogramming 
subsequently went into decline for a long time, because further master transcription 
factors were not easy to discover. 
 In the last decade, the emergence of iPS cells has completely changed the situa-
tion for direct reprogramming studies [ 21 ,  22 ]. After the discovery of iPS cells, it 
was found that sets of transcription factors, rather than single transcription factors, 
could be successively identiﬁ ed as master regulators capable of inducing fate 
conversion of cells. At present, various types of cells have been induced from 
ﬁ broblasts, including neurons [ 29 ], cardiomyocytes [ 30 ], hepatocytes [ 31 ,  32 ], 
adipocytes [ 33 ], Sertoli cells [ 34 ], and chondrocytes [ 35 ]. Furthermore, not only 
ﬁ broblasts but also other types of cells, such as hepatocytes [ 36 ], astrocytes [ 37 ], 
Sertoli cells [ 38 ], and B cells [ 39 ], have been employed as sources of cells for direct 
reprogramming. These ﬁ ndings imply that direct reprogramming technology will 
become a universal method for almost all kinds of cells. Although the recent studies 
on direct reprogramming are summarized in Table  1 , studies on direct reprogram-
ming are continuing to increase year by year.
 Regarding successful cases of direct reprogramming, three different cell lineages, 
cardiomyocytes, neurons, and hepatocytes, can be considered to be well- investigated 
targets for the following reasons: (1) functional failure of these cells is critical for 
the survival of individuals; (2) a number of patients suffer from diseases associated 
with malfunction of these cells; and (3) a large number of cells should be prepared 
in vitro prior to application of these cells for transplantation therapies. Among these 
three cell types, cardiomyocytes could be considered to be the most widely studied 
cells in the ﬁ eld of direct reprogramming. Following the publication of the ﬁ rst 
report by Ieda et al. [ 30 ], several groups reported similar methods for cardiomyocyte 
reprogramming [ 40 – 47 ]. However, the transcription factors used for the induction 
of cardiomyocyte-like cells were different in each study (Table  1 ), and the properties 
of the cells were also inhomogeneous [ 30 ,  40 – 47 ]. The obtained evidence suggested 
ﬂ exibility in the molecular mechanisms underlying direct  reprogramming and a 
necessity for standardized protocols toward therapeutic applications. 
 The molecular machinery for the direct induction of neuronal cells in vitro can 
be considered to be the most deeply investigated example in the ﬁ eld of direct repro-
gramming. Vierbuchen et al. [ 29 ] showed that three transcription factors, Brm2, 
Ascl1, and Myt1l, induced conversion of mouse ﬁ broblasts into neuron-like cells, 
designated induced neuronal (iN) cells. iN cells had neuron-speciﬁ c characteristics, 
including neurite outgrowth, expression of speciﬁ c neuronal markers, and electro-
physiological activities. In addition to the discovery of iN cells, the same group 
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 Table 1  Recent examples of direct reprogramming studies 
 Target cell  Source cell  Factors used  Species  References 
 Neuronal cell  Embryonic 
ﬁ broblast 
 Brn2, Ascl1, 
and Myt1l 
 Mouse  Vierbuchen 
et al. [ 29 ] 
 Glutamatergic 
neuron 
 Cortical astrocyte  Ngn2  Mouse  Berninger et al. 
[ 56 ]; Heinrich 
et al. [ 57 ] 
 GABAergic 
neuron 
 Cortical astrocyte  Dlx2, or Dlx2 
and Ascl1 
 Mouse  Heinrich et al. 
[ 57 ] 
 Neuronal cell  Hepatocyte  Brn2, Ascl1, 
and Myt1l 










et al. [ 58 ] 
 Neuronal cell  Fetal/postnatal 
ﬁ broblast 
 Brn2, Ascl1, 
Myt1l, and NeuroD1 
 Human  Pang et al. [ 59 ] 
 Neuronal cell  Neonatal foreskin/
adult dermal 
ﬁ broblast 
 Ascl1, Brn2, Myt1l, 
Lmx1a, and Foxa2 
 Human  Pﬁ sterer 
et al. [ 60 ] 
 Neuronal cell  Astrocyte  Brn4  Mouse  Potts et al. [ 37 ] 
 Neural stem cell  Sertoli cell  Pax6, Ngn2, Hes1, 
Id1, Ascl1, Brn2, 
cMyc, and Klf4 
 Mouse  Sheng et al. [ 38 ] 
 Cardiomyocyte  Cardiac ﬁ broblast  Gata4, Mef2c, and Tbx5  Mouse  Ieda et al. [ 30 ] 
 Cardiomyocyte  Cardiac ﬁ broblast  miR-1, 133, 208, 
and 499 
 Mouse  Jayawardena 
et al. [ 40 ] 
 Cardiomyocyte  Cardiac ﬁ broblast  Gata4, Mef2c, 
Tbx5, and Hand2 
 Mouse  Song et al. [ 41 ] 
 Cardiomyocyte  Cardiac ﬁ broblast  Gata4, Mef2c, 
and Tbx5 
 Mouse  Chen et al. [ 42 ] 
 Cardiomyocyte  Cardiac/embryonic 
ﬁ broblast 
 Mef2c, Tbx5 + 
Myocd or Gata4 
 Mouse  Protze et al. [ 43 ] 
 Cardiomyocyte  Embryonic 
ﬁ broblast 
 Gata4, Tbx5, Hand2, 
and Myod M3 domain 
fused with Mef2c 
 Mouse  Hirai et al. [ 44 ] 
 Cardiomyocyte  Dermal ﬁ broblast  GATA4, MEF2C, TBX5, 
MESP1, and MYOCD 
 Human  Wada et al. [ 45 ] 
 Cardiomyocyte  Dermal ﬁ broblast  GATA4, MEF2C, TBX5, 
ESRRG, MESP1, 
ZFPM2, and MYOCD 
 Human  Fu et al. [ 46 ] 
 Cardiomyocyte  Cardiac/embryonic 
ﬁ broblast 
 Gata4, Mef2c, 
Tbx5 + miR133 or 




et al. [ 47 ] 
 Hepatocyte  Embryonic/dermal 
ﬁ broblast 
 Hnf4α + Foxa1, 2, or 3  Mouse  Sekiya and 
Suzuki [ 31 ] 
(continued)
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Table 1 (continued)
 Target cell  Source cell  Factors used  Species  References 
 Hepatocyte  Tail-tip ﬁ broblast  Gata4, Hnf1α, Foxa3, 
and p19 Arf KD 
 Mouse  Huang et al. [ 32 ] 
 Hepatocyte  Fetal limb 
ﬁ broblast 
 FOXA3, HNF1A, 
HNF4A, and SV40 Large 
T antigen 
 Human  Huang et al. [ 53 ] 
 Hepatocyte  Embryonic 
ﬁ broblast 
 HNF1A, HNF4A, 
HNF6, ATF5, 
PROX1, CEBP, 
MYC, and TP53 KD 
 Human  Du et al. [ 54 ] 
 Hepatocyte  Neonatal ﬁ broblast  HNF1A + FOXA1, 
FOXA3, or HNF4A 
(mRNA) 
 Human  Simeonov and 
Uppal [ 52 ] 
 Sertoli cell  Embryonic 
ﬁ broblast 
 Nr5a1, Wt1, Dmrt1, 
Gata4, and Sox9 
 Mouse  Buganim 
et al. [ 34 ] 
 Chondrocyte  Dermal ﬁ broblast  KLF4, MYC, 
and SOX9 
 Human  Tam et al. [ 35 ] 
 Erythroid cell  B cell  Gata1, Scl, 
and Cebpa 
 Mouse  Sadahira 
et al. [ 39 ] 
 T cell  B cell  Pax5 KO  Mouse  Cobaleda 
et al. [ 61 ] 
 Monocyte  Skin ﬁ broblast  Spl1, Cebpa, Mnda, 
and Irf8 
 Mouse  Suzuki et al. 
[ 62 ] 
 Macrophage  Pre-T cell  Cebpa or Cebpb  Mouse  Laiosa et al. [ 63 ] 
 Macrophage-like 
cell 
 3 T3 cell, 
embryonic/skin 
ﬁ broblast 
 Pu.1 + Cebpa or Cebpb  Mouse  Feng et al. [ 64 ] 




dermal ﬁ broblast 
 OCT4 + hematopoietic 
cytokine treatment 
 Human  Szabo et al. [ 65 ] 
 Megakaryocyte  3 T3 cell, dermal 
ﬁ broblast 









 Foxn1  Mouse  Bredenkamp 
et al. [ 67 ] 
 Vascular 
endothelial cell 
 Amniotic cell  ETV2, FLI1, ERG1 
with TGFB inhibition 
 Human  Ginsberg 
et al. [ 68 ] 
 Β cell  Pancreatic exocrine 
cell 
 Ngn3, Pdx1, and Mafa  Mouse  Zhou et al. [ 69 ] 
 Brown fat cell  Skin ﬁ broblast  Prdm16 and Cebpb  Mouse/
human 
 Kajimura 
et al. [ 70 ] 
 Pancreatic 
islet cell 
 Hepatocyte  Ngn3  Mouse  Desgraz and 
Herrera [ 71 ] 
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revealed that remarkable epigenetic remodeling occurred in iN cells, and that Ascl1 
acted as a pioneering factor that could activate closed chromatins during the repro-
gramming [ 48 ]. A better understanding of the molecular mechanisms controlling 
direct cell-fate conversion could provide great advantages for the development and 
application of direct reprogramming technology. 
 Direct Reprogramming of Fibroblasts to Hepatocytes 
 As mentioned above, functionally mature hepatocytes are strongly demanded for 
clinical use. To supply hepatocytes safely and stably without any ethical problems, 
direct reprogramming of patient-derived non-hepatic cells into hepatocytes appears 
to be a preferable method. Such newly generated hepatocytes could be technologi-
cally and economically useful for future cell-based regenerative therapies for liver 
diseases. The ﬁ rst studies showing direct conversion of non-hepatic cells into 
hepatocyte- like cells were independently reported by two groups: one was from 
our group [ 31 ] and the other was from Hui’s group [ 31 ,  32 ] (Fig.  1 ). Although 
both groups induced conversion of mouse ﬁ broblasts into hepatocyte-like cells, 
Hnf4α +
Foxa1, 2, or 3
(Sekiya and Suzuki 2011 [31]) 
Hnf1α, Foxa3, Gata4,
and p19Arf knockdown
(Huang et al. 2011 [32])
HNF1A, HNF4A, FOXA3,
and SV40 Large T antigen
(Huang et al. 2014 [53])
HNF1A, HNF4A, HNF6,
ATF5, PROX1, CEBP, MYC,
and siRNA for TP53





 Fig. 1  Direct reprogramming of ﬁ broblasts to iHep cells. iHep cells can be induced by various 
protocols 
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the transcription factors used were different. Our group found that three 
combinations of two transcription factors, comprising a hepatocyte nuclear recep-
tor, Hnf4α [ 49 ], and members of the forkhead domain-containing transcription 
factor family, Foxa1, Foxa2, and Foxa3 [ 50 ], could induce conversion of ﬁ broblasts 
into hepatocyte-like cells, designated induced hepatocyte-like (iHep) cells [ 31 ]. 
In contrast, Hui’s group used a combination of three transcription factors, Gata4, 
Hnf1α, and Foxa3, with siRNA-based suppression of the expression of a tumor 
suppressor, p19 Arf [ 32 ]. Although the reprogramming factors were different, iHep 
cells could be induced in both methods, and their morphological and functional 
properties were similar [ 31 ,  32 ]. These ﬁ ndings suggest the presence of lineage-
speciﬁ c core transcriptional networks that can determine the fate of cells.
 iHep cells have multiple hepatocyte-speciﬁ c properties: (1) the morphology and 
gene expression pattern of iHep cells resemble those of epithelial cells; (2) iHep 
cells express hepatocyte-speciﬁ c genes and proteins; (3) iHep cells have functional 
features of hepatocytes, including glycogen storage, LDL uptake, ammonium 
metabolism, urea production, cytochrome P450 activity, and drug metabolism; and 
(4) iHep cells can reconstitute liver tissues, ameliorate hepatic functions of recipient 
mice, and rescue mice from a deadly hepatic disorder, hereditary tyrosinemia type 
I, upon transplantation into the liver of a mouse model of the disease. In addition to 
these features, we recently showed that iHep cells possess the potential to be 
involved in lipid metabolism, similar to hepatocytes [ 51 ]. These ﬁ ndings suggest 
that iHep cells are useful not only for screening of drugs, but also for the treatment 
of patients with fatty liver diseases. The morphology and function of iHep cells do 
not become attenuated during culture or after freeze-preservation, which could be 
great advantages in the application of iHep cells to cell-based regenerative therapies 
for liver diseases. 
 The above-mentioned characteristics suggest that iHep cells could be a potent 
cell source for future cell transplantation therapies. However, three problems remain 
to be resolved. First, the level of hepatic function is lower in iHep cells than in pri-
mary hepatocytes. Therefore, for use of iHep cells in cell transplantation therapies, 
the level of hepatic function in iHep cells needs to be improved by inducing the 
maturation of these cells. Second, viral vectors need to be excluded from the repro-
gramming procedures, because integration of the virus genomes into the host 
genomes may induce malignant transformation of cells. Thus, other reprogramming 
strategies using chemical compounds, growth factors, or non-integrative vectors are 
expected to be practical. Recently, Simeonov and Uppal [ 52 ] demonstrated the 
potential utility of an mRNA transfection-based technique for the generation of 
iHep cells. This technology may contribute to safer induction of iHep cells. Third, 
application of iHep cell technology to human cells is still in the development stage. 
Recently, two different groups reported data on the induction of human iHep cells 
[ 53 ,  54 ]. These studies showed that the technology for iHep cell generation in 
mouse cells could be reproducible in human cells. However, there are some critical 
differences between the methods for mouse and human iHep cell induction. In the 
case of human iHep cells, activation of MYC and SV40 large T antigen and sup-
pression of TP53 are included in the methods for iHep cell generation, which have 
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a risk for inducing malignant transformation of these cells (Fig.  1 ). Thus, it is 
expected that human iHep cells capable of proliferation without growth boosters, 
which can avoid the risk of tumorigenesis, should be generated for the application 
of iHep cells in transplantation therapies. 
 Conversely, Zhu et al. [ 55 ] reported a completely different strategy for induction 
of hepatocytes in vitro. They initially used OCT4, KLF4, SOX2, and MYC to 
induce iPS cells. However, they interrupted the conversion process of iPS cells and 
continued the culture of partially reprogrammed intermediate cells in the presence 
of various growth factors and chemical compounds that are known inducers of 
hepatic differentiation. The resultant hepatocyte-like cells showed hepatocyte- 
speciﬁ c features like iHep cells. Thus, this method could be another alternative to 
stem cell–based regenerative therapies for liver failures, as well as the technology of 
iHep cell generation. 
 Conclusions 
 Cell-based regenerative medicine is one of the most promising clinical technologies 
in the treatment of liver disorders. However, it has remained unclear whether cell- 
based therapies are actually available in clinical settings without any risk for 
patients. To reduce the associated risks, the methods for cellular reprogramming 
and differentiation procedures should be improved in ES cell, iPS cell, and iHep cell 
technologies. As one of the important approaches, we need to understand the 
molecular mechanisms underlying the generation of iHep cells and the differentia-
tion of hepatocytes, with a view to updating the technology for direct reprogram-
ming and actualizing the functional maturation of iHep cells for use in cell-based 
regenerative therapies toward liver diseases. We believe that many current efforts in 
basic research will open up a new horizon for next-generation therapies using 
directly reprogrammed cells. 
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